[go: up one dir, main page]

PL352775A1 - Preparaty farmaceutyczne lewodopa/karbidopa/entakapon - Google Patents

Preparaty farmaceutyczne lewodopa/karbidopa/entakapon

Info

Publication number
PL352775A1
PL352775A1 PL00352775A PL35277500A PL352775A1 PL 352775 A1 PL352775 A1 PL 352775A1 PL 00352775 A PL00352775 A PL 00352775A PL 35277500 A PL35277500 A PL 35277500A PL 352775 A1 PL352775 A1 PL 352775A1
Authority
PL
Poland
Prior art keywords
carbidopa
levodopa
pharmaceutical preparation
entacapone
entacapone pharmaceutical
Prior art date
Application number
PL00352775A
Other languages
English (en)
Other versions
PL197818B1 (pl
Inventor
Sari Kallioinen
Lasse Kervinen
Marja Laaksonen
Jarmo Lintulaakso
Mervi Niskanen
Marja Partanen
Marja Ritala
Kari Vahervuo
Matti Virkki
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL352775(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of PL352775A1 publication Critical patent/PL352775A1/pl
Publication of PL197818B1 publication Critical patent/PL197818B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PL352775A 1999-06-30 2000-06-29 Stałe doustne kompozycje lewodopa/karbidopa/entakapon, sposób ich wytwarzania oraz ich zastosowanie PL197818B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus
PCT/FI2000/000593 WO2001001984A1 (en) 1999-06-30 2000-06-29 Levodopa / carbidopa / entacapone pharmaceutical preparation

Publications (2)

Publication Number Publication Date
PL352775A1 true PL352775A1 (pl) 2003-09-08
PL197818B1 PL197818B1 (pl) 2008-04-30

Family

ID=8554988

Family Applications (1)

Application Number Title Priority Date Filing Date
PL352775A PL197818B1 (pl) 1999-06-30 2000-06-29 Stałe doustne kompozycje lewodopa/karbidopa/entakapon, sposób ich wytwarzania oraz ich zastosowanie

Country Status (42)

Country Link
US (2) US6500867B1 (pl)
EP (1) EP1189608B1 (pl)
JP (2) JP4204783B2 (pl)
KR (1) KR100905428B1 (pl)
CN (1) CN1168440C (pl)
AR (1) AR033796A1 (pl)
AT (1) ATE245417T1 (pl)
AU (1) AU765932B2 (pl)
BG (1) BG65364B1 (pl)
BR (2) BRPI0011867B8 (pl)
CA (1) CA2378469C (pl)
CO (1) CO5180579A1 (pl)
CZ (2) CZ304416B6 (pl)
DE (1) DE60004052T2 (pl)
DK (1) DK1189608T3 (pl)
EA (1) EA004503B1 (pl)
EE (1) EE05473B1 (pl)
ES (1) ES2203495T3 (pl)
FI (1) FI109453B (pl)
FR (1) FR2797587A1 (pl)
GE (1) GEP20043314B (pl)
HK (1) HK1047040B (pl)
HR (1) HRP20020088B1 (pl)
HU (1) HU230395B1 (pl)
IL (1) IL146807A (pl)
IT (1) ITMI20001450A1 (pl)
ME (1) ME00520B (pl)
MX (1) MXPA01013167A (pl)
MY (1) MY127685A (pl)
NO (2) NO330260B1 (pl)
NZ (1) NZ515780A (pl)
PE (1) PE20010399A1 (pl)
PL (1) PL197818B1 (pl)
PT (1) PT1189608E (pl)
RS (1) RS50368B (pl)
SI (1) SI1189608T1 (pl)
SK (1) SK286451B6 (pl)
TR (1) TR200103763T2 (pl)
TW (1) TWI241187B (pl)
UA (1) UA75047C2 (pl)
WO (1) WO2001001984A1 (pl)
ZA (1) ZA200109868B (pl)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
EP1560569A4 (en) * 2002-10-11 2006-03-22 Depomed Dev Ltd GASTRORETENTIVE LEVODOPA DELIVERY FORM
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
US20060241183A1 (en) * 2004-09-28 2006-10-26 Farouk Karoum Compositions and methods of using D-DOPA to treat Parkinson's disease
JP2008519811A (ja) 2004-11-10 2008-06-12 オリオン コーポレーション 下肢静止不能症候群の治療
US20080187590A1 (en) * 2005-06-08 2008-08-07 Kari Vahervuo Oral Dosage Form
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
BRPI0613859B8 (pt) 2005-07-26 2021-05-25 Bial Portela & Ca Sa inibidores da comt, seus usos, e composição farmacêutica
WO2007016190A2 (en) * 2005-07-28 2007-02-08 Duke University Antiparkinsonian action of phenylisopropylamines
US20090012170A1 (en) * 2005-09-21 2009-01-08 Helena Nissinen Treatment of symptoms of motor dysfunction
WO2007056570A2 (en) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Levodopa compositions
US8772346B2 (en) * 2005-11-09 2014-07-08 Torrent Pharmaceuticals Limited Pharmaceutical composition
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (en) * 2006-03-31 2007-10-11 Iprbox Oy Pharmaceutical composition and preparation method thereof
EP1845097A1 (en) 2006-04-10 2007-10-17 Portela & Ca., S.A. Oxadiazole derivatives as COMT inhibitors
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008053297A2 (en) * 2006-10-30 2008-05-08 Wockhardt Research Centre Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008081268A2 (en) * 2006-12-27 2008-07-10 Wockhardt Research Centre Pharmaceutical compositions of entacapone
EP1946756A1 (en) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Use of entacapone in cosmetic, dermatological and pharmaceutical compositions
SI2481410T1 (sl) 2007-01-31 2017-01-31 Bial - Portela & Ca., S.A. Derivati nitrokatehola kot COMT inhibitorji, ki se dajejo s specifičnim dozirnim režimom
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
KR101444979B1 (ko) * 2008-02-06 2014-10-07 욱크하르트 리미티드 생체 이용율이 개선된 엔타카폰, 레보도파 및 카르비도파의 약학 조성물
PL2293791T3 (pl) * 2008-02-06 2012-04-30 Wockhardt Ltd Kompozycje farmaceutyczne entakaponu współ-mikronizowanego z alkoholami cukrowymi
TW200942531A (en) 2008-03-17 2009-10-16 Bial Portela & Companhia S A Crystal forms of a nitrocatechol
ES2476792T3 (es) 2008-08-22 2014-07-15 Wockhardt Limited Composición farmacéutica de dosis oral unitaria única que comprende levodopa, carbidopa y entacapona o sales de las mismas
CN102170870A (zh) * 2008-08-22 2011-08-31 沃克哈特研究中心 恩他卡朋或其盐的缓释药物组合物
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (en) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa
RU2701731C2 (ru) 2009-04-01 2019-10-01 Биал-Портела Энд Ка, С.А. Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
US8193243B2 (en) * 2009-05-19 2012-06-05 Neuroderm, Ltd. Continuous administration of dopa decarboxylase inhibitors and compositions for same
EP2517704B1 (en) * 2009-12-25 2019-05-01 Innopharmax, Inc. Pharmaceutical composition for treating parkinson's disease and preparation method thereof
CN102781424B (zh) * 2010-03-04 2016-03-30 奥赖恩公司 左旋多巴、卡比多巴和恩他卡朋用于治疗帕金森病的应用
DE102010023828A1 (de) 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
JP5902705B2 (ja) * 2010-11-15 2016-04-13 ニューロダーム リミテッドＮｅｕｒｏｄｅｒｍ Ｌｔｄ Ｌ−ドーパ、ドーパデカルボキシラーゼ阻害剤、カテコール−ｏ−メチルトランスフェラーゼ阻害剤、およびそれらのための組成物の継続的投与
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (en) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Pharmaceutical composition
WO2012147099A1 (en) 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Pharmaceutical compositions of levodopa, carbidopa and entacapone
JP5855230B2 (ja) * 2011-04-26 2016-02-09 イノファーマックス インコーポレイテッド エンタカポン組成物
EP2791134B1 (en) 2011-12-13 2019-09-25 BIAL - Portela & Cª S.A. Chemical compound useful as intermediate for preparing a catechol-o-methyltransferase inhibitor
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
MX2014014902A (es) 2012-06-05 2015-03-04 Neuroderm Ltd Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
WO2014141261A1 (en) * 2013-03-13 2014-09-18 Neuroderm Ltd Method for treatment of parkinson's disease
EP2799065A1 (en) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Levodopa carbidopa entacapone pharmaceutical formulations
EP3782614A1 (en) 2013-10-07 2021-02-24 Impax Laboratories, LLC Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP4299128A3 (en) 2014-03-13 2024-04-17 Neuroderm Ltd. Dopa decarboxylase inhibitor compositions
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3188725B1 (en) 2014-09-04 2020-10-28 Lobsor Pharmaceuticals Aktiebolag Pharmaceutical compositions comprising levodopa, a dopamine decarboxylase inhibitor and a comt inhibitor and method of administration thereof
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
EP3236957A1 (en) 2014-12-23 2017-11-01 Pharmathen S.A. Levodopa/carbidopa/entacapone pharmaceutical preparation and method for preparing the same
WO2017039525A1 (en) 2015-09-04 2017-03-09 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
US11975104B2 (en) * 2016-07-11 2024-05-07 Contera Pharma A/S Pulsatile drug delivery system for treating morning akinesia
EP3500246B1 (en) 2016-08-18 2021-08-04 Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi Antiparkinson tablet formulation with improved dissolution profile
WO2019145773A1 (en) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Liposomal-encapsulated formulations
KR20250043584A (ko) 2018-03-23 2025-03-28 롭서 파마슈티컬스 악티에볼라그 신경퇴행성 장애의 치료를 위한 약제학적 조성물의 연속 투여
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
WO2022140448A1 (en) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus

Also Published As

Publication number Publication date
MXPA01013167A (es) 2002-07-02
HUP0202273A2 (en) 2002-10-28
BR0011867A (pt) 2002-03-05
CN1168440C (zh) 2004-09-29
NZ515780A (en) 2004-06-25
KR100905428B1 (ko) 2009-06-30
HK1047040A1 (en) 2003-02-07
TWI241187B (en) 2005-10-11
GEP20043314B (en) 2004-02-10
JP2003503454A (ja) 2003-01-28
PL197818B1 (pl) 2008-04-30
CZ304416B6 (cs) 2014-04-23
IL146807A (en) 2006-10-05
RS50368B (sr) 2009-11-10
CZ303010B6 (cs) 2012-02-29
HUP0202273A3 (en) 2002-11-28
ZA200109868B (en) 2003-05-28
NO20016203D0 (no) 2001-12-18
US6797732B2 (en) 2004-09-28
ITMI20001450A0 (it) 2000-06-28
CA2378469A1 (en) 2001-01-11
JP2008156373A (ja) 2008-07-10
JP4204783B2 (ja) 2009-01-07
BG65364B1 (bg) 2008-04-30
CZ20014636A3 (cs) 2002-05-15
SI1189608T1 (en) 2004-04-30
BRPI0011867B1 (pt) 2019-01-08
DE60004052T2 (de) 2004-04-15
HRP20020088A2 (en) 2005-10-31
EA004503B1 (ru) 2004-04-29
ITMI20001450A1 (it) 2001-12-28
WO2001001984A1 (en) 2001-01-11
CA2378469C (en) 2009-10-06
FR2797587A1 (fr) 2001-02-23
EP1189608A1 (en) 2002-03-27
FI991485A0 (fi) 1999-06-30
DE60004052D1 (de) 2003-08-28
ATE245417T1 (de) 2003-08-15
AU765932B2 (en) 2003-10-02
US20030017201A1 (en) 2003-01-23
SK19232001A3 (sk) 2002-06-04
PE20010399A1 (es) 2001-04-10
HU230395B1 (hu) 2016-04-28
EE200100716A (et) 2003-02-17
HK1047040B (zh) 2005-04-29
AU5830600A (en) 2001-01-22
BG106251A (en) 2002-08-30
YU92501A (sh) 2004-09-03
DK1189608T3 (da) 2003-11-10
US6500867B1 (en) 2002-12-31
CO5180579A1 (es) 2002-07-30
MY127685A (en) 2006-12-29
NO20110090L (no) 2002-02-25
ES2203495T3 (es) 2004-04-16
ME00520B (me) 2011-10-10
HRP20020088B1 (hr) 2007-05-31
UA75047C2 (en) 2006-03-15
EA200200106A1 (ru) 2002-06-27
EE05473B1 (et) 2011-10-17
BRPI0011867B8 (pt) 2021-05-25
TR200103763T2 (tr) 2002-04-22
KR20020010155A (ko) 2002-02-02
NO330260B1 (no) 2011-03-14
EP1189608B1 (en) 2003-07-23
JP4885896B2 (ja) 2012-02-29
SK286451B6 (sk) 2008-10-07
FI109453B (fi) 2002-08-15
AR033796A1 (es) 2004-01-07
NO20016203L (no) 2002-02-25
PT1189608E (pt) 2003-12-31
CN1358090A (zh) 2002-07-10
FI991485L (fi) 2000-12-31

Similar Documents

Publication Publication Date Title
HRP20020088A2 (en) Levodopa/carbidopa/entacapone pharmaceutical preparation
GB9907263D0 (en) Amino acid derivatives
CZ20011518A3 (cs) Farmaceutický prostředek
DE69841871D1 (en) Dipeptide nitrile
GB2348924B (en) Fastener
SI1112065T1 (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose deivative
PL344834A1 (en) Pharmaceutical levothyroxine preparation
AU1780395A (en) Amino acid, carnitine and magnesium supplementation
ZA982073B (en) Pharmaceutical preparation
HU229988B1 (en) Aqueous lysine solution
IL146152A0 (en) Prucalopride oral solution
SI0951465T1 (en) Alpha-amino acid amides, preparation thereof and the therapeutical use thereof
TW385640U (en) Fastener
GB0007602D0 (en) Cycles
GB9910935D0 (en) Amino acid sequence
IL149635A0 (en) Solid preparation
GB0018504D0 (en) Antipyretic composition
GB9828707D0 (en) Pharmaceutical uses
GB2369664B (en) Fastener
FI20011892A0 (fi) Menetelmä entakaponia, levodopaa ja karbidopaa sisältävän farmaseuttisen koostumuksen valmistamiseksi
SG85133A1 (en) Alimentary integrator
GB9810160D0 (en) Short amino acid sequence
GB0025386D0 (en) Branched amino acids
TW433418U (en) Fastener
GB9910034D0 (en) Fastener